Diagnostic and clinical utility of exome sequencing and chromosomal microarray in children with GDD/iD: a meta-analysis
Open Access
- 30 December 2025
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2609424
Abstract
Global developmental delay/intellectual disability (GDD/ID) is among the most common neurodevelopmental disorders, with up to half of cases are attributed to genetic factors. Chromosome microarray (CMA) has traditionally been the primary genetic test for idiopathic GDD/ID. However, whole exome sequencing (WES) and whole genome sequencing (WGS) have recently emerged, substantially increasing diagnostic yields in these populations. We conducted a comprehensive literature search of PubMed, Scopus, EMBASE, and the Cochrane Library from inception to April 29, 2025. Studies reporting the diagnostic utility of these tests in children with GDD/ID were included and analyzed. A total of 102 studies, comprising 55,752 children, were reviewed. The pooled diagnostic yield of WES was 0.37 (95% CI: 0.33-0.41; I2 = 93%), significantly higher than that of CMA at 0.19 (95% CI: 0.16-0.21; I2 = 95%). Subgroup analyses showed that WES yielded significantly higher diagnostic rates than CMA in both same-sample comparisons (OR = 2.27, 95% CI: 1.08-4.78) and different-sample comparisons (OR = 1.65, 95% CI: 1.15-2.37). Only one study evaluated WGS, reporting a diagnostic yield of 0.27. Meta-regression revealed a significant association between CMA diagnostic yield and the proportion of male participants (p < 0.01), but not with WES. No significant difference in diagnostic utility was observed between isolated GDD/ID and GDD/ID with comorbidities. In children with unexplained GDD/ID, WES demonstrates superior diagnostic and clinical utility compared to CMA. Incorporating WES as a first-line investigation in the diagnostic evaluation of GDD/ID may be warranted.Keywords
This publication has 123 references indexed in Scilit:
- Diagnostic Utility of Trio–Exome Sequencing for Children With Neurodevelopmental DisordersJAMA Network Open, 2025
- Proband‐Only Exome Sequencing for Intellectual Disability in Iran: Diagnostic Yield and Genetic InsightsAmerican Journal of Medical Genetics Part A, 2024
- The diagnostic yield of genetic and metabolic investigations in syndromic and nonsyndromic patients with autism spectrum disorder, global developmental delay, or intellectual disability from a dedicated neurodevelopmental disorders genetics clinicAmerican Journal of Medical Genetics Part A, 2024
- Genetic Testing for Global Developmental Delay in Early ChildhoodJAMA Network Open, 2024
- Whole genome sequencing of 45 Japanese patients with intellectual disabilityAmerican Journal of Medical Genetics Part A, 2021
- Marked yield of re‐evaluating phenotype and exome/target sequencing data in 33 individuals with intellectual disabilitiesAmerican Journal of Medical Genetics Part A, 2017
- Comorbidity of intellectual disability confounds ascertainment of autism: implications for genetic diagnosisAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015
- Changing interpretation of chromosomal microarray over time in a community cohort with intellectual disabilityAmerican Journal of Medical Genetics Part A, 2013
- Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse dataStatistics in Medicine, 2010
- Application of metaphase HR‐CGH and targeted chromosomal microarray analyses to genomic characterization of 116 patients with mental retardation and dysmorphic featuresAmerican Journal of Medical Genetics Part A, 2008